Grzegorz Sienski

Grzegorz Sienski

Auto-generated profile, based on publicly available information

Grzegorz Sienski

Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GSGrzegorz Sienski
Grzegorz Sienski
PNPriyanka Narayan
Priyanka Narayan
JBJulia Maeve Bonner
Julia Maeve Bonner
NKNora Kory
Nora Kory
SBSebastian Boland
Sebastian Boland
SLSusan Lindquist
Susan Lindquist
APOE4 -disrupted intracellular lipid homeostasis in human and yeast cells was reversed by promoting phospholipid synthesis through choline supplementation.

24 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMartin Peterka
Martin Peterka
NANina Akrap
Nina Akrap
SLSongyuan Li
Songyuan Li
SWSandra Wimberger
Sandra Wimberger
PHPei-Pei Hsieh
Pei-Pei Hsieh
MMMarcello Maresca
Marcello Maresca
Prime editing recently emerged as a next-generation approach for precise genome editing. Here we exploit DNA double-strand break (DSB) repair to develop two strategies that install precise genomic insertions using an SpCas9 nuclease-based prime editor (PEn). We first demonstrate that PEn coupled to a regular prime editing guide RNA (pegRNA) efficiently promotes short genomic insertions through a homology-dependent DSB repair mechanism. While PEn editing leads to increased levels of by-products, it can rescue pegRNAs that perform poorly with a nickase-based prime editor. We also present a small molecule approach that yields increased product purity of PEn editing. Next, we develop a homology-independent PEn editing strategy, which installs genomic insertions at DSBs through the non-homologous end joining pathway (NHEJ). Lastly, we show that PEn-mediated insertions at DSBs prevent Cas9-induced large chromosomal deletions and provide evidence that continuous Cas9-mediated cutting is one of the mechanisms by which Cas9-induced large deletions arise. Altogether, this work expands the current prime editing toolbox by leveraging distinct DNA repair mechanisms including NHEJ, which represents the primary pathway of DSB repair in mammalian cells.

21 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLSongyuan Li
Songyuan Li
NANina Akrap
Nina Akrap
SCSilvia Cerboni
Silvia Cerboni
MPMichelle J. Porritt
Michelle J. Porritt
SWSandra Wimberger
Sandra Wimberger
MMMarcello Maresca
Marcello Maresca
Prokaryotic restriction enzymes, recombinases and Cas proteins are powerful DNA engineering and genome editing tools. However, in many primary cell types, the efficiency of genome editing remains low, impeding the development of gene- and cell-based therapeutic applications. A safe strategy for robust and efficient enrichment of precisely genetically engineered cells is urgently required. Here, we screen for mutations in the receptor for Diphtheria Toxin (DT) which protect human cells from DT. Selection for cells with an edited DT receptor variant enriches for simultaneously introduced, precisely targeted gene modifications at a second independent locus, such as nucleotide substitutions and DNA insertions. Our method enables the rapid generation of a homogenous cell population with bi-allelic integration of a DNA cassette at the selection locus, without clonal isolation. Toxin-based selection works in both cancer-transformed and non-transformed cells, including human induced pluripotent stem cells and human primary T-lymphocytes, as well as it is applicable also in vivo, in mice with humanized liver. This work represents a flexible, precise, and efficient selection strategy to engineer cells using CRISPR-Cas and base editing systems.

14 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KPKasparas Petkevicius
Kasparas Petkevicius
HPHenrik Palmgren
Henrik Palmgren
MGMatthew S. Glover
Matthew S. Glover
AAAndrea Ahnmark
Andrea Ahnmark
AAAnne-Christine Andréasson
Anne-Christine Andréasson
XPXiao-Rong Peng
Xiao-Rong Peng
The fatty acid composition of phosphatidylethanolamine (PE) determines cellular metabolism, oxidative stress, and inflammation. However, our understanding of how cells regulate PE composition is limited. Here, we identify a genetic locus on mouse chromosome 11, containing two poorly characterized genes Tlcd1 and Tlcd2, that strongly influences PE composition. We generated Tlcd1/2 double-knockout (DKO) mice and found that they have reduced levels of hepatic monounsaturated fatty acid (MUFA)-containing PE species. Mechanistically, TLCD1/2 proteins act cell intrinsically to promote the incorporation of MUFAs into PEs. Furthermore, TLCD1/2 interact with the mitochondria in an evolutionarily conserved manner and regulate mitochondrial PE composition. Lastly, we demonstrate the biological relevance of our findings in dietary models of metabolic disease, where Tlcd1/2 DKO mice display attenuated development of non-alcoholic steatohepatitis compared to controls. Overall, we identify TLCD1/2 proteins as key regulators of cellular PE composition, with our findings having broad implications in understanding and treating disease.

5 December 2024 in Stem Cell Reports
Verified
Journal Article
Open access
ARAntje K. Rottner
Antje K. Rottner
ALAnders Lundin
Anders Lundin
SLSongyuan Li
Songyuan Li
MFMike Firth
Mike Firth
MMMarcello Maresca
Marcello Maresca
GSGrzegorz Sienski
Grzegorz Sienski
Gene editing strategies to safely and robustly modify the Alzheimer's disease-associated APOE4 isoform are still lacking. Prime editing (PE) enables the precise introduction of genetic variants with minimal unintended editing and without donor templates. However, it requires optimization for each target site and has not yet been applied to APOE4 gene editing. Here, we screened PE guide RNA (pegRNA) parameters and PE systems for introducing the APOE4 variant and applied the optimized PE strategy to generate disease-relevant human induced pluripotent stem cell models. We show that introducing a single-nucleotide difference required for APOE4 correction inhibits PE activity. To advance efficient and robust genome engineering of precise genetic variants, we further present a reliable PE enrichment strategy based on diphtheria toxin co-selection. Our work provides an optimized and reproducible genome engineering pipeline to generate APOE4 disease models and outlines novel strategies to accelerate genome editing in cellular disease model generation.

7 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DDDmitrii Degtev
Dmitrii Degtev
JBJack Bravo
Jack Bravo
AEAikaterini Emmanouilidi
Aikaterini Emmanouilidi
AZAleksandar Zdravković
Aleksandar Zdravković
OCOi Kuan Choong
Oi Kuan Choong
GSGrzegorz Sienski
Grzegorz Sienski
Clinical implementation of therapeutic genome editing relies on efficient in vivo delivery and the safety of CRISPR-Cas tools. Previously, we identified PsCas9 as a Type II-B family enzyme capable of editing mouse liver genome upon adenoviral delivery without detectable off-targets and reduced chromosomal translocations. Yet, its efficacy remains insufficient with non-viral delivery, a common challenge for many Cas9 orthologues. Here, we sought to redesign PsCas9 for in vivo editing using lipid nanoparticles. We solve the PsCas9 ribonucleoprotein structure with cryo-EM and characterize it biochemically, providing a basis for its rational engineering. Screening over numerous guide RNA and protein variants lead us to develop engineered PsCas9 (ePsCas9) with up to 20-fold increased activity across various targets and preserved safety advantages. We apply the same design principles to boost the activity of FnCas9, an enzyme phylogenetically relevant to PsCas9. Remarkably, a single administration of mRNA encoding ePsCas9 and its guide formulated with lipid nanoparticles results in high levels of editing in the Pcsk9 gene in mouse liver, a clinically relevant target for hypercholesterolemia treatment. Collectively, our findings introduce ePsCas9 as a highly efficient, and precise tool for therapeutic genome editing, in addition to the engineering strategy applicable to other Cas9 orthologues.